JSC Olainfarm has won the International World Health Organization (WHO) tender for the supply of anti-tuberculosis agent PASS sodium in 2019 - 2020. Based on the results of the tender, WHO and Latvian pharmaceutical company Olainfarm has signed a contract for the delivery of this medicine for more than 3 million euros. The first delivery of PASS sodium will take place already in April.
“We are proud to be a cooperation partner with WHO for almost 10 years, proving the high quality of Olainfarm's medicines. The safety of raw materials, high evaluation of the product quality, compliance with delivery terms and long-term positive cooperation experience are the criteria that has allowed Olainfarm to re-win the WHO tender for delivery of this anti-tuberculosis drug also in 2019 and 2020,” underscores Lauris Macijevskis, the Chairman of the Management Board of JSC Olainfarm.
The PASS sodium salt was one of the 15 most sold Olainfarm products in 2018. Besides the WHO, Olainfarm supplies PASS sodium salt also to specialized clinical centers in the Baltic States, international NGO Doctors without borders (Médecins Sans Frontières), and export to Moldova.
The PASS sodium is one of the best-known anti-tuberculosis agents in the world, and has been widely used by WHO to treat tuberculosis in developing countries in Asia and Africa. Olainfarm has been producing this medicine since 2001, but since 2011 the company has qualified as a WHO partner in anti-tuberculosis program, regularly participating in WHO procurement tenders.
The first effective tuberculosis medicines were developed in the 1940s. In Western Europe and North America, cases of tuberculosis are very rare, but a large part of the world still has to deal with it every day. As evident from the WHO Global Tuberculosis Report 2018, there were about 10 million tuberculosis patients worldwide in 2017. 30 countries with the highest prevalence of tuberculosis accounted for 87% of all cases. Thanks to massive anti-tuberculosis initiatives implemented in the long term, the number of new diagnoses worldwide has been shrinking by an average of 2% annually; the 2020 target is to reduce the number of new cases by 4-5% every year.
JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with 45 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company's operations is to produce reliable and effective top- quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 60 countries worldwide, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.